STOCK TITAN

Agios to Present at March Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor conferences:

  • Cowen 41st Annual Virtual Healthcare Conference on Monday, March 1, 2021 at 11:40 a.m. ET; and
  • Oppenheimer 31st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 9:20 a.m. ET.

Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

About Agios
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.

Contacts

Investors & Media:
Holly Manning, 617-844-6630
Director, Investor Relations
Holly.Manning@agios.com


Agios Pharmaceuticals Inc

NASDAQ:AGIO

AGIO Rankings

AGIO Latest News

AGIO Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Cambridge

About AGIO

at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible